Rifampicin tolerance and growth fitness among isoniazid-resistant clinical Mycobacterium tuberculosis isolates from a longitudinal study
eLife · 2024
DOI: 10.7554/elife.93243 ↗Kurz gefasst
Fachartikel in der Zeitschrift eLife, 2024. Verfasst von Srinivasan Vijay und 15 weiteren Autor:innen. Beteiligte Einrichtung: Oxford University Clinical Research Unit, Ho Chi Minh, Viet Nam. Hauptthemen laut MEDLINE: Rifampin, Mycobacterium tuberculosis, Isoniazid, Microbial Sensitivity Tests. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, NIAID NIH HHS, National Institute of Allergy and Infectious Diseases.
Abstract (Originalsprache)
Antibiotic tolerance in Mycobacterium tuberculosis reduces bacterial killing, worsens treatment outcomes, and contributes to resistance. We studied rifampicin tolerance in isolates with or without isoniazid resistance (IR). Using a minimum duration of killing assay, we measured rifampicin survival in isoniazid-susceptible (IS, n=119) and resistant (IR, n=84) isolates, correlating tolerance with bacterial growth, rifampicin minimum inhibitory concentrations (MICs), and isoniazid-resistant mutations. Longitudinal IR isolates were analyzed for changes in rifampicin tolerance and genetic variant emergence. The median time for rifampicin to reduce the bacterial population by 90% (MDK90) increased from 1.23 days (IS) and 1.31 days (IR) to 2.55 days (IS) and 1.98 days (IR) over 15–60 days of incubation, indicating fast and slow-growing tolerant sub-populations. A 6 log10-fold survival fraction classified tolerance as low, medium, or high, showing that IR is linked to increased tolerance and faster growth (OR = 2.68 for low vs. medium, OR = 4.42 for low vs. high, p-trend = 0.0003). High tolerance in IR isolates was associated with rifampicin treatment in patients and genetic microvariants. These findings suggest that IR tuberculosis should be assessed for high rifampicin tolerance to optimize treatment and prevent the development of multi-drug-resistant tuberculosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Oxford University Clinical Research Unit, Ho Chi Minh, Viet Nam.
- Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
- Theoretical Microbial Ecology, Institute of Microbiology, Faculty of Biological Sciences, Friedrich Schiller University, Jena, Germany.
- Cluster of Excellence Balance of the Microverse, Friedrich Schiller University Jena, Jena, Germany.
- Pham Ngoc Thach Hospital, Ho Chi Minh, Viet Nam.
- Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom.
ORCID-Profile: Srinivasan Vijay, Guy E Thwaites, Nguyen Thuy Thuong
Förderung
- Wellcome Trust
- NIAID NIH HHS
- National Institute of Allergy and Infectious Diseases
Zitieren
APA
Vijay, S., Bao, N. L. H., Vinh, D. N., Nhat, L. T. H., Thu, D. D. A., Quang, N. L., Trieu, L. P. T., Nhung, H. N., Ha, V. T. N., Thai, P. V. K., Ha, D. T. M., Lan, N. H., Caws, M., Thwaites, G. E., Javid, B., & Thuong, N. T. (2024). Rifampicin tolerance and growth fitness among isoniazid-resistant clinical Mycobacterium tuberculosis isolates from a longitudinal study. eLife. https://doi.org/10.7554/elife.93243
Vancouver
Vijay S, Bao NLH, Vinh DN, Nhat LTH, Thu DDA, Quang NL, et al. Rifampicin tolerance and growth fitness among isoniazid-resistant clinical Mycobacterium tuberculosis isolates from a longitudinal study. eLife. 2024. doi:10.7554/elife.93243
BibTeX
@article{Vijay2024,
author = {Vijay, Srinivasan and Bao, Nguyen Le Hoai and Vinh, Dao Nguyen and Nhat, Le Thanh Hoang and Thu, Do Dang Anh and Quang, Nguyen Le and Trieu, Le Pham Tien and Nhung, Hoang Ngoc and Ha, Vu Thi Ngoc and Thai, Phan Vuong Khac and Ha, Dang Thi Minh and Lan, Nguyen Huu and Caws, Maxine and Thwaites, Guy E and Javid, Babak and Thuong, Nguyen Thuy},
title = {Rifampicin tolerance and growth fitness among isoniazid-resistant clinical Mycobacterium tuberculosis isolates from a longitudinal study},
journal = {eLife},
year = {2024},
doi = {10.7554/elife.93243}
}
EUVIMED